Myelodysplastic syndromes are a complex and heterogenous group of clonal myeloid neoplasms, characterised by ineffective ...

Bruce Feinberg, DO: Amer, we’ve heard about it, and it’s clear that everyone involved—from the patient to the primary caregiver and the specialist and the pharmacist supporting the team—that everybody ...

Somatic mutations with effects similar to those seen with VEXAS syndrome are increasingly seen as possible drivers of ...

The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Demonstrates Robust and Sustained Hematologic Response in Subjects with IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome ...

Myelodysplastic syndromes, also called myelodysplasia or MDS, is the name for a group of conditions that cause the number of normal blood cells to drop. In these syndromes, the bone marrow does not ...

RPT1G is the first well-tolerated NAMPT inhibitor, demonstrating safety in healthy volunteers at single and multiple ascending dose levels.Target ...

Risk scoring methods continue to evolve with increased understanding of the factors that affect specific patient group outcomes in MDS. Diagnosis of MDS is currently based on morphology, but can be ...

Allogeneic hematopoietic cell transplantation (HCT) offers the only potential cure for patients with myelodysplastic syndromes (MDS). However, with current approaches to HCT, many older patients with ...

Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven ...

DelveInsight’s, “Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory ...